LOS ANGELES--(BUSINESS WIRE)--
Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that
develops and distributes prescription medical foods, convenience kits
and generic pharmaceuticals to physicians and pharmacies, today
announced the appointment of William B. Horne as the company’s Chief
Financial Officer. He will oversee all aspects of the company’s fiscal
operations and financial reporting.
“I am very pleased to have William join our growing management team,”
said William Shell, M.D., the company’s CEO and Chief Science Officer.
“His leadership and financial experience in the public and private
healthcare sectors is a tremendous asset for Targeted Medical Pharma as
we continue to execute on our growth strategy, driven by the increasing
demand for cost-effective therapeutic alternatives such as medical foods
across the healthcare sector.”
Horne brings to Targeted Medical Pharma a combination of experience in
both early stage and mature environments with a 20-year record of
success at managing corporate financial operations for fast-growing
private and public companies. Horne previously held the position of CFO
at various companies, including OptimisCorp, a privately held
healthcare technology company, and Patient Safety Technologies, Inc.
(OTCBB: PSTX), a publicly traded medical device company. He also held
supervisory positions at Price Waterhouse, LLP and received a Bachelor
of Arts in Accounting from Seattle University where he graduated magna
About Targeted Medical Pharma, Inc.
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops prescription medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company manufactures 10 proprietary
prescription-only medical foods, as well as 48 convenience packed kits,
which pair a medical food and branded or generic pharmaceutical. These
prescription medical foods and therapeutic systems are sold to
physicians and pharmacies in the U.S through the company’s subsidiary, Physician
Therapeutics. These proprietary medications represent a novel
approach to the management of certain disease states, focusing on safety
and efficacy without the deleterious side effects of traditional, high
dose prescription drugs. The company is developing nutrient-based
systems for oral stimulation of progenitor stem cells that differentiate
into neurons, red blood cells, pituitary hormones including IGF-I.
Targeted Medical Pharma also provides diagnostic testing as well as
billing and collection services on behalf of dispensing physicians.
Forward Looking Statement
This press releasemay contain forward-looking statements
related to the company’s business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaim any obligation or
undertaking to update or revise any forward-looking statement contained
herein to reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances upon which
any statement is based.
Medici | firstname.lastname@example.org
Neal | email@example.com
Jeff Ramson | firstname.lastname@example.org
Source: Targeted Medical Pharma, Inc.